Key message
In this study we demonstrate that strong anti-mycobacterial responses can be achieved by targeting Mycobacterium tuberculosis antigens to dendritic cells via the human DC-SIGN receptor
Translational perspective
This study provides the proof of concept for a novel dendritic cell-based vaccine against tuberculosis. This is of clinical relevance given that there is a constant need for the development of new vaccine candidates since BCG, the only available vaccine, is unable to protect against pulmonary tuberculosis, the most prevalent form of the disease in adults.